PDCD1 and cancer: With an altered approach, a combination of CRISPR/Cas9 knockout of PD-1 from patient T cells to improve persistence [111], and viral transduction to express two CARs targeted against both CD39 and CD73, could result in potent anti-cancer effect by increasing immunogenicity of the microenvironment.